Related Experiment Video
Updated: Jun 4, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Genomics for disease treatment and prevention
Cinnamon S Bloss1, Dilip V Jeste, Nicholas J Schork
1The Scripps Translational Science Institute, 3344 North Torrey Pines Court, La Jolla, CA 92037, USA.
The Psychiatric Clinics of North America
|February 22, 2011
Summary
Genetics and genomics advances offer personalized medicine for healthcare, including mental health. This review examines clinical applications, social factors, and future research needs in genomic medicine.
Area of Science:
- Genomic Medicine
- Personalized Healthcare
- Translational Genomics
Background:
- Recent decades have seen significant progress in genetics and genomics.
- These advances hold promise for transforming healthcare delivery.
- The integration of genomic data into clinical practice is rapidly evolving.
Purpose of the Study:
- To review the history and progress of genetics and genomics.
- To assess the current clinical utility of genetic and genomic findings for disease prevention and treatment.
- To identify key social, economic, and policy considerations for genomic medicine and future research priorities.
Main Methods:
- Literature review of historical developments in genetics and genomics.
- Analysis of current clinical applications of genomic discoveries.
- Examination of socio-economic and policy factors influencing genomic medicine adoption.
- Identification of research gaps and future directions.
Main Results:
- Genetics and genomics have the potential to revolutionize healthcare, leading to personalized medicine.
- Clinical application of genomic findings is still emerging but growing.
- Social, economic, and policy factors significantly impact the integration of genomic medicine.
Conclusions:
- Genomic medicine is poised to reshape healthcare, emphasizing personalized approaches.
- Further research is needed to fully leverage genetic and genomic discoveries for clinical benefit.
- Addressing social, economic, and policy challenges is crucial for advancing genomic medicine.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:02Genomics
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:46Genetic Screens
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...